PURPOSE: The purpose of this study is to describe the relationships between full-field stimulus threshold (FST), electroretinography (ERG), and visual field (VF) outcomes in retinitis pigmentosa (RP). METHODS: Data from 47 patients with RP (n = 94 eyes) were evaluated. Patients were submitted to comprehensive ophthalmological examination including measurement of best-corrected visual acuity (BCVA), 30-2 threshold static VF, and microperimetry. Full-field ERG (ISCEV standard) was recorded, and achromatic FST was measured using a Diagnosys Espion system with the ColorDome™ LED full-field stimulator (Diagnosys LLC, Lowell, MA, USA). RESULTS: BCVA mean ± SD was 0.31 ± 0.03 logMAR, and FST mean ± SD was -18.45 ± 9.53 dB. No significant correlation was found between BCVA and FST. In contrast, statistically significant correlations were found between FST and static 30-2 VF mean deviation (r = -0.389; P < 0.01), microperimetry mean threshold (r = -0.607; P < 0.01). Dark and light-adapted ERGs were detectable in 28 and 48 eyes, respectively. Nevertheless, considering only the eyes with recordable ERG responses, moderate correlations were found between combined dark-adapted a-wave amplitude (r = -0.560; P < 0.01), b-wave amplitude (r = -0.643; P < 0.001), 30-Hz flicker response (r = -0.501; P < 0.01), and FST, and high correlation with FST for cone b-wave amplitude (r = -0.715; P < 0.01). CONCLUSIONS: FST could be successfully determined in RP patients with a wide range of vision loss. FST results showed stronger correlations with full-field ERG amplitude than with sensitivity measured with visual field tests. FST is as an alternative to VF or ERG for assessment of retinal function in patients unable to do visual fields or with non-detectable ERGs.
PURPOSE: The purpose of this study is to describe the relationships between full-field stimulus threshold (FST), electroretinography (ERG), and visual field (VF) outcomes in retinitis pigmentosa (RP). METHODS: Data from 47 patients with RP (n = 94 eyes) were evaluated. Patients were submitted to comprehensive ophthalmological examination including measurement of best-corrected visual acuity (BCVA), 30-2 threshold static VF, and microperimetry. Full-field ERG (ISCEV standard) was recorded, and achromatic FST was measured using a Diagnosys Espion system with the ColorDome™ LED full-field stimulator (Diagnosys LLC, Lowell, MA, USA). RESULTS:BCVA mean ± SD was 0.31 ± 0.03 logMAR, and FST mean ± SD was -18.45 ± 9.53 dB. No significant correlation was found between BCVA and FST. In contrast, statistically significant correlations were found between FST and static 30-2 VF mean deviation (r = -0.389; P < 0.01), microperimetry mean threshold (r = -0.607; P < 0.01). Dark and light-adapted ERGs were detectable in 28 and 48 eyes, respectively. Nevertheless, considering only the eyes with recordable ERG responses, moderate correlations were found between combined dark-adapted a-wave amplitude (r = -0.560; P < 0.01), b-wave amplitude (r = -0.643; P < 0.001), 30-Hz flicker response (r = -0.501; P < 0.01), and FST, and high correlation with FST for cone b-wave amplitude (r = -0.715; P < 0.01). CONCLUSIONS: FST could be successfully determined in RP patients with a wide range of vision loss. FST results showed stronger correlations with full-field ERG amplitude than with sensitivity measured with visual field tests. FST is as an alternative to VF or ERG for assessment of retinal function in patients unable to do visual fields or with non-detectable ERGs.
Authors: Alejandro J Roman; Sharon B Schwartz; Tomas S Aleman; Artur V Cideciyan; John D Chico; Elizabeth A M Windsor; Leigh M Gardner; Gui-Shuang Ying; Elaine E Smilko; Maureen G Maguire; Samuel G Jacobson Journal: Exp Eye Res Date: 2005-02 Impact factor: 3.467
Authors: Katherine E Talcott; Kavitha Ratnam; Sanna M Sundquist; Anna S Lucero; Brandon J Lujan; Weng Tao; Travis C Porco; Austin Roorda; Jacque L Duncan Journal: Invest Ophthalmol Vis Sci Date: 2011-04-06 Impact factor: 4.799
Authors: M S Humayun; E de Juan; M del Cerro; G Dagnelie; W Radner; S R Sadda; C del Cerro Journal: Invest Ophthalmol Vis Sci Date: 2000-09 Impact factor: 4.799
Authors: William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson Journal: Hum Gene Ther Date: 2008-10 Impact factor: 5.695
Authors: Eberhart Zrenner; Karl Ulrich Bartz-Schmidt; Heval Benav; Dorothea Besch; Anna Bruckmann; Veit-Peter Gabel; Florian Gekeler; Udo Greppmaier; Alex Harscher; Steffen Kibbel; Johannes Koch; Akos Kusnyerik; Tobias Peters; Katarina Stingl; Helmut Sachs; Alfred Stett; Peter Szurman; Barbara Wilhelm; Robert Wilke Journal: Proc Biol Sci Date: 2010-11-03 Impact factor: 5.349
Authors: Virginia Miraldi Utz; Wanda Pfeifer; Susannah Q Longmuir; Richard John Olson; Kai Wang; Arlene V Drack Journal: JAMA Ophthalmol Date: 2018-04-01 Impact factor: 7.389
Authors: Olga Zabek; Giacomo Calzetti; Dominique Prétot; Hendrik P N Scholl; Maria Della Volpe Waizel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2022-03-31 Impact factor: 3.535
Authors: Rubens C Siqueira; Andre Messias; Katharina Messias; Rafael S Arcieri; Milton A Ruiz; Neiglene F Souza; Lia C Martins; Rodrigo Jorge Journal: Stem Cell Res Ther Date: 2015-03-14 Impact factor: 6.832
Authors: Thomas L Edwards; Charles L Cottriall; Kanmin Xue; Matthew P Simunovic; James D Ramsden; Eberhart Zrenner; Robert E MacLaren Journal: Ophthalmology Date: 2017-10-27 Impact factor: 12.079
Authors: Xuan-Thanh-An Nguyen; Mays Talib; Mary J van Schooneveld; Joost Brinks; Jacoline Ten Brink; Ralph J Florijn; Jan Wijnholds; Robert M Verdijk; Arthur A Bergen; Camiel J F Boon Journal: Int J Mol Sci Date: 2020-01-28 Impact factor: 5.923